Skip Navigation
National Institutes of Health: National Cancer Institute: Division of Cancer Control and Population Sciences
Grant Details

Grant Number: 7R01CA116758-03 Interpret this number
Primary Investigator: Shahinian, Vahakn
Organization: University Of Michigan
Project Title: Gnrh Agonists for Prostate Cancer: Role of the Urologist
Fiscal Year: 2006
Back to top


Abstract

DESCRIPTION (provided by applicant): There is uncertainty regarding the efficacy of androgen deprivation therapy for earlier stages of prostate cancer. In addition, there are serious toxicities and a substantial financial cost associated with this therapy, particularly with the use of gonadotropin-releasing hormone (GnRH) agonists, which are now the predominant form of androgen deprivation. In the face of these concerns, recent studies have shown a dramatic rise in the use of GnRH agonists for prostate cancer over the 1990s, even in settings where there is no evidence of survival benefit. Wide differences in rates of GnRH agonist use between geographic regions suggest the presence of variations in practice patterns, possibly reflecting provider uncertainty about the risks and benefits of this therapy. We hypothesize that the provider plays an important role in influencing the observed time trends and variations in use of GnRH agonists for prostate cancer. This study will use linked SEER Medicare data and American Medical Association data to achieve the following objectives: 1) describe the variation among providers in use of GnRH agonists, 2) examine the effect of provider characteristics on the likelihood of use of GnRH agonists for prostate cancer and 3) determine the provider characteristics that influenced the change in use of GnRH agonists for prostate cancer over the 1990s. Collectively, the information derived from this proposal will help direct efforts at provider education and monitoring the use of GnRH agonists for prostate cancer. This will be especially important as more information on the risks and benefits of GnRH agonists become available, with the ultimate goal being the provision of quality care for men with prostate cancer.

Back to top


Publications

Risk Of The "androgen Deprivation Syndrome" In Men Receiving Androgen Deprivation For Prostate Cancer
Authors: Shahinian V.B. , Kuo Y.F. , Freeman J.L. , Goodwin J.S. .
Source: Archives Of Internal Medicine, 2006-02-27 00:00:00.0; 166(4), p. 465-71.
PMID: 16505268
Related Citations

Determinants Of Androgen Deprivation Therapy Use For Prostate Cancer: Role Of The Urologist
Authors: Shahinian V.B. , Kuo Y.F. , Freeman J.L. , Goodwin J.S. .
Source: Journal Of The National Cancer Institute, 2006-06-21 00:00:00.0; 98(12), p. 839-45.
PMID: 16788157
Related Citations

Comparison Of Stage At Diagnosis Of Cancer In Patients Who Are On Dialysis Versus The General Population
Authors: Taneja S. , Mandayam S. , Kayani Z.Z. , Kuo Y.F. , Shahinian V.B. .
Source: Clinical Journal Of The American Society Of Nephrology : Cjasn, 2007 Sep; 2(5), p. 1008-13.
PMID: 17702737
Related Citations

Characteristics Of Urologists Predict The Use Of Androgen Deprivation Therapy For Prostate Cancer
Authors: Shahinian V.B. , Kuo Y.F. , Freeman J.L. , Orihuela E. , Goodwin J.S. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2007-12-01 00:00:00.0; 25(34), p. 5359-65.
PMID: 18048816
Related Citations

Gonadotropin-releasing Hormone Agonist Use In Men Without A Cancer Registry Diagnosis Of Prostate Cancer
Authors: Kuo Y.F. , Goodwin J.S. , Shahinian V.B. .
Source: Bmc Health Services Research, 2008; 8, p. 146.
PMID: 18620606
Related Citations

Cause Of Death In Older Men After The Diagnosis Of Prostate Cancer
Authors: Ketchandji M. , Kuo Y.F. , Shahinian V.B. , Goodwin J.S. .
Source: Journal Of The American Geriatrics Society, 2009 Jan; 57(1), p. 24-30.
PMID: 19054189
Related Citations

Prevalent And Incident Use Of Androgen Deprivation Therapy Among Men With Prostate Cancer In The United States
Authors: Gilbert S.M. , Kuo Y.F. , Shahinian V.B. .
Source: Urologic Oncology, 2011 Nov-Dec; 29(6), p. 647-53.
PMID: 19926311
Related Citations